Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Coya Therapeutics, Inc., retaining the price target of $18.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors including Coya Therapeutics’ recent successful equity financing and the company’s strong financial position. The completion of the equity financing raised approximately $23 million, providing Coya with sufficient resources to fund operations into the second half of 2027. This financial stability is further supported by the company’s cash reserves of $28.1 million as of the end of the third quarter of 2025.
Additionally, several upcoming catalysts are expected to drive value for Coya Therapeutics. These include milestone payments linked to the ALS trial, publication of biomarker data, and the release of clinical data from trials in Alzheimer’s and frontotemporal dementia. The potential for these developments to positively impact the company’s valuation underpins the Buy rating and the 12-month price target of $18.
Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, BridgeBio Pharma, and Genmab. According to TipRanks, Selvaraju has an average return of 19.7% and a 53.92% success rate on recommended stocks.
In another report released on November 13, Lake Street also maintained a Buy rating on the stock with a $17.00 price target.